Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Prat on the Differences Between EndoPredict and Prosigna

June 9th 2014

Aleix Prat, MD, PhD, medical oncologist, Vall D'Hebron Institute of Oncology, Barcelona, Spain, discusses the differences between EndoPredict and Prosigna.

2014 NCCN Guideline Updates: Experts Highlight New Recommendations for Clinical Practice

June 6th 2014

At the recent National Comprehensive Cancer Network (NCCN) 19th Annual Conference, experts discussed this year's updates to the NCCN Clinical Practice Guidelines in Oncology. The meeting also included reviews of NCCN Task Force reports on issues in supportive care. We asked eleven NCCN panel members to select the most significant updates and insights presented at the conference.

Practice-Changing Data Revealed for Premenopausal HR+ Breast Cancer

June 2nd 2014

A joint analysis of two phase III trials involving a total of 4690 premenopausal women with hormone-receptorâ€“positive (HR+) breast cancer demonstrated that adjuvant use of the aromatase inhibitor (AI), exemestane, reduced relative risk of developing subsequent invasive cancer by 28% compared with tamoxifen when both agents were combined with ovarian function suppression (OFS).

Negative ALTTO Results Reverberate for Lapatinib, Novel Clinical Trials

June 1st 2014

A dual HER2-blockade strategy that added lapatinib to trastuzumab for the adjuvant treatment of women with early breast cancer failed to demonstrate a significant improvement in DFS over the standard therapy with trastuzumab alone.

Dr. Pegram on a Phase II Trial of MGAH22 in Breast Cancer

June 1st 2014

Mark D. Pegram, MD, from the Stanford University Medical Center, discusses a phase II study of margetuximab in patients with relapsed or refractory advanced breast cancer whose tumors express HER2 at the 2+ level by immunohistochemistry and lack evidence of HER2 gene amplification by FISH.

Dr. Yardley on Enzalutamide Plus Exemestane in HR-Positive Breast Cancer

May 31st 2014

Denise A. Yardley, MD, hematologist/oncologist, Sarah Cannon Research Institute discusses a pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer when given enzalutamide plus exemestane.

Goserelin Preserves Fertility, Aids Survival During Breast Cancer Chemo

May 31st 2014

Adding goserelin to chemotherapy for women with early-stage hormone receptor (HR)-negative breast cancer helps both to preserve their fertility and to prolong their survival.

Zoledronic Acid Can Be Administered Less Frequently in Breast Cancer

May 31st 2014

The dosing frequency of zoledronic acid can be reduced by 67% without compromising efficacy and safety in women with breast cancer and bone metastases.

2nd Annual Giants of Cancer Care Awards Honor Leading Researchers

May 30th 2014

The ballots are in, and 16 leading researchers whose discoveries have propelled the field of cancer treatment forward will be honored during the 2014 Giants of Cancer Care award ceremony on May 30 at Riva Restaurant on Navy Pier in Chicago.

Dr. Formenti on Concurrent Adjuvant Systemic Therapy and Accelerated Radiotherapy in TNBC

May 29th 2014

Silvia Formenti, MD, The Sandra and Edward H. Meyer Professor of Radiation Oncology chair, Radiation Oncology, NYU Langone Medical Center, associate director, Radiation Oncology, Perlmutter Cancer Center at NYU Langone, discusses a trial that examines concurrent adjuvant systemic therapy and accelerated radiotherapy in triple-negative breast cancer (TNBC)

ASCO Guideline Recommends 10 Years of Tamoxifen in HR-positive Breast Cancer

May 27th 2014

The ASCO clinical practice guideline now recommends treatment with adjuvant tamoxifen for 10 years in women with stage I-III hormone receptor-positive breast cancer.

Studies Link Higher Vitamin D Levels With Improved Cancer Prognosis

May 23rd 2014

Two recently published clinical studies demonstrated a strong association between higher levels of vitamin D and improved outcomes among patients with various cancers.

Dr. White Describes the BR-002 Trial in Breast Cancer

May 22nd 2014

Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, describes the BR-002 trial for patients with breast cancer.

Update on Novel Drug Targets in Metastatic Breast Cancer

May 16th 2014

More recently, researchers seek to understand the mechanisms related to tumor dissemination in hopes of therapeutically targeting this process.

For Premenopausal Women With ER-Positive Disease, Obesity Is a Major Risk Factor in Breast Cancer Mortality

May 14th 2014

Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease.

Dr. Muss Discusses Evaluating Cardiac Toxicity in Patients With Breast Cancer

May 12th 2014

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses evaluating cardiac toxicity in patients with breast cancer.

Dr. Kuerer on the Overtreatment of DCIS

May 9th 2014

Henry M. Kuerer, MD, PhD, FACS, professor of surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses the overtreatment of DCIS.

Dr. Salerno on Donations to Breast Cancer Research

May 7th 2014

Judith A. Salerno, MD, MS, president, CEO, Susan G. Komen, comments on donations to breast cancer research.

New Options for Low-Risk, HER2-Positive Tumors Featured in Research Overview

May 7th 2014

Fresh insights into outcomes for patients with low-risk, HER2-positive breast cancer suggest that adjuvant chemotherapy regimens with or without trastuzumab (Herceptin) should be considered as options for managing this growing population

Dr. Boughey Discusses Breast Conservation in Patients with Multiple Ipsilateral Tumors

May 5th 2014

Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, on breast conservation in patients with multiple ipsilateral tumors.